ImpediMed Limited
IPDQF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 8.5% | 15.7% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | $0 | -$0 |
| % Margin | – | 88.1% | 87.7% | -163.6% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $0 | $0 | $0 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | -$0 | $0 |
| Operating Expenses | – | $0 | -$0 | $0 |
| Operating Income | – | -$0 | $0 | -$0 |
| % Margin | – | -192.7% | 190.3% | -252.6% |
| Other Income/Exp. Net | – | $0 | -$0 | $0 |
| Pre-Tax Income | – | -$0 | -$0 | -$0 |
| Tax Expense | – | $0 | $0 | -$0 |
| Net Income | – | -$0 | -$0 | -$0 |
| % Margin | – | -185.5% | -182% | -203.1% |
| EPS | – | 0 | -0.005 | -0.005 |
| % Growth | – | 100% | 0% | – |
| EPS Diluted | – | 0 | -0.005 | -0.005 |
| Weighted Avg Shares Out | – | 2,229 | 2 | 2 |
| Weighted Avg Shares Out Dil | – | 2,023 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $0 | $0 |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | -156% | -195.7% | -110.7% |